Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spicing things up: synthetic cannabinoids.
Spaderna M, Addy PH, D'Souza DC. Spaderna M, et al. Psychopharmacology (Berl). 2013 Aug;228(4):525-40. doi: 10.1007/s00213-013-3188-4. Epub 2013 Jul 9. Psychopharmacology (Berl). 2013. PMID: 23836028 Free PMC article. Review.
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.
Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS. Krystal JH, et al. Psychopharmacology (Berl). 1998 Feb;135(3):213-29. doi: 10.1007/s002130050503. Psychopharmacology (Berl). 1998. PMID: 9498724 Free article. Clinical Trial.
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.
Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS. Krystal JH, et al. Psychopharmacology (Berl). 1999 Jul;145(2):193-204. doi: 10.1007/s002130051049. Psychopharmacology (Berl). 1999. PMID: 10463321 Clinical Trial.
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Abi-Saab W, et al. Psychopharmacology (Berl). 2002 Jun;162(1):55-62. doi: 10.1007/s00213-002-1057-7. Epub 2002 Apr 5. Psychopharmacology (Berl). 2002. PMID: 12107618 Clinical Trial.
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Krystal JH, et al. Psychopharmacology (Berl). 2005 Apr;179(1):303-9. doi: 10.1007/s00213-004-1982-8. Epub 2004 Aug 10. Psychopharmacology (Berl). 2005. PMID: 15309376 Clinical Trial.
Greater vulnerability to the amnestic effects of ketamine in males.
Morgan CJ, Perry EB, Cho HS, Krystal JH, D'Souza DC. Morgan CJ, et al. Psychopharmacology (Berl). 2006 Sep;187(4):405-14. doi: 10.1007/s00213-006-0409-0. Epub 2006 Aug 1. Psychopharmacology (Berl). 2006. PMID: 16896964 Clinical Trial.
Cannabinoids and psychosis.
D'Souza DC. D'Souza DC. Int Rev Neurobiol. 2007;78:289-326. doi: 10.1016/S0074-7742(06)78010-2. Int Rev Neurobiol. 2007. PMID: 17349865 Review.
Psychiatric safety of ketamine in psychopharmacology research.
Perry EB Jr, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O'Donnell E, Krystal JH, D'Souza DC; Yale Ketamine Study Group. Perry EB Jr, et al. Psychopharmacology (Berl). 2007 Jun;192(2):253-60. doi: 10.1007/s00213-007-0706-2. Epub 2007 Feb 16. Psychopharmacology (Berl). 2007. PMID: 17458544 Review.
182 results